New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:36 EDTMRK, SSNLF, BIIBMerck, Samsung Bioepis enter collaboration agreement
Merck (MRK) and Samsung Bioepis, a joint venture between Samsung (SSNLF) Biologics and Biogen (BIIB), announced that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Under the terms of the agreement, the companies will collaborate on clinical development, regulatory filings and manufacturing. If approved, Merck will commercialize this candidate. This collaboration builds on the agreement made by the two companies in February 2013 to develop and commercialize multiple biosimilar candidates.
News For MRK;SSNLF;BIIB From The Last 14 Days
Check below for free stories on MRK;SSNLF;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 16, 2014
10:52 EDTSSNLFApple, China Mobile trade lower as iPhone 6 unlikely to debut in China this year
Subscribe for More Information
09:13 EDTSSNLFApple may need to wait until 2015 to launch iPhone 6 in China, Bloomberg says
Subscribe for More Information
07:31 EDTMRKEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:25 EDTMRKMerck price target raised to $72 from $62 at SunTrust
After meeting with Merck's CEO and head of clinical development, SunTrust increased its price target on the company as the firm thinks that it is ideally positioned across five of the fastest growing therapeutic classes. The firm believes that the company's EPS growth rates from 2015-2020 will be three percentage points above Street estimates, while it has a first-mover advantage in oncology. It keeps a Buy rating on the shares.
06:28 EDTSSNLFLenovo, Huawei look to pose threat in high-end smartphone segment, DigiTimes says
Subscribe for More Information
September 15, 2014
13:30 EDTMRKMerck announces data from pivotal Phase 3 study for odanacatib
Merck announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Merck’s investigational once-weekly cathepsin K inhibitor. In the Long-Term Odanacatib Fracture Trial, odanacatib met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with placebo. The rates of adverse events overall in LOFT were generally balanced between patients taking odanacatib and placebo. Adjudicated events of morphea-like skin lesions and atypical femoral fractures occurred more often in the odanacatib group than in the placebo group. Adjudicated major adverse cardiovascular events were generally balanced overall between the treatment groups. There were numerically more adjudicated stroke events with odanacatib than with placebo.
08:01 EDTBIIBAlnylam names Karen Anderson as SVP, Chief Human Resources Officer
Subscribe for More Information
06:25 EDTSSNLFWearable orders appear optimistic in 2014, DigiTimes reports
Supply chains are seeing optimistic demand throughout 2014 for wearables, reports DigiTimes. Makers are seeing orders for flexible AMOLED panels and component orders for 1.56-inch panels. Reference Link
September 14, 2014
14:41 EDTSSNLFSamsung asks for investigation of LG Electronics on vandalism, WSJ says
Subscribe for More Information
September 12, 2014
07:32 EDTBIIBBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
06:30 EDTSSNLFGlobal tablet shipments to increase 9.1% in Q3, DigiTimes Research reports
Subscribe for More Information
September 11, 2014
07:31 EDTBIIBBiogen announces 5-year results from TECFIDERA ENDORSE Phase 3 study
Subscribe for More Information
07:31 EDTBIIBBiogen announces new data from Plegridy Phase 3 ADVANCE trial
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY were maintained in people with relapsing forms of multiple sclerosis beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis in Boston. Post-hoc analyses from the two-year, Phase 3 ADVANCE clinical trial confirm that PLEGRIDY’s positive effects on reducing disease activity and disability progression were maintained in year two of the study. A significantly higher proportion of patients taking PLEGRIDY during both years of the study experienced no evidence of disease activity – defined as the absence of clinical and MRI disease activity over two years of treatment – compared to those who switched to PLEGRIDY from placebo. Also, those treated with PLEGRIDY for both years of the study had significant reductions in the risk of 24-week confirmed disability progression compared to patients treated with placebo during the first year. In addition, new data from the second year of ADVANCE show that patients who took PLEGRIDY throughout the study experienced statistically significant improvements in clinical and MRI outcomes – including annualized relapse rate, risk of relapse, risk of 24-week confirmed disability progression, and number of brain lesions – when compared to those who switched to PLEGRIDY after taking placebo for the first year. This new data also showed that the safety profile of PLEGRIDY was consistent between years one and two of the study.
September 10, 2014
16:00 EDTMRKOptions Update; September 10, 2014
Subscribe for More Information
10:03 EDTSSNLFAmerican Airlines to use electronic flight attendent manuals
Subscribe for More Information
06:21 EDTSSNLFSamsung's panel orders expected to remain strong till Q4, DigiTimes says
Subscribe for More Information
06:17 EDTSSNLFDRAMeXchange: DRAM industyr profits to stabilize in 2015, DigiTimes reports
DRAM industry profits are expected to stabilize in 2015 as construction of Samsung and SK Hynix's new fabrication plants will not be finished till next year, reports DigiTimes. Citing DRAMeXchange, a significant increase in capacity at Samsung's Line 17 fab initially scheduled for 2Q12 has been delayed. Production will begin at 10,000 wafer starts a month in the second quarter of 2015 and increase gradually to 40,000 wafer starts by the end of the year. Reference Link
September 9, 2014
08:37 EDTSSNLFBarnes & Noble's NOOK launched first co-branded tablet with Samsung
Subscribe for More Information
07:29 EDTSSNLFUBM Canon to hold a summit
Subscribe for More Information
06:20 EDTSSNLFForrester: Apple could sell 10M iWatches this year, FT reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use